Search Results
Your search for Jo Cavallo matches 25 pages
Showing 1 - 25Molecular Profiles of BRAF-Mutant Melanomas and Response to Therapy
A study investigating the clinicopathologic features of BRAF V600E– and V600K–mutant melanomas and whether genotype affects response to immunotherapy found that the mutations not only have different clinical phenotypes, but also different molecular features and different...
First-Line Treatment With Checkpoint Inhibitors in Patients With Melanoma Brain Metastases
An analysis of newly diagnosed patients with cutaneous melanoma brain metastases treated with checkpoint blockade immunotherapy has found the treatment was associated with an increase in median overall survival of 12.4 months compared with 5.2 months—a 1.4-fold improvement. The benefit was...
Older Patients With Melanoma Fare Better on Anti–PD-1 Immunotherapy Than Younger Patients
Recent research has shown that the tumor microenvironment in older patients promoted melanoma metastasis and resistance to targeted therapy with a BRAF inhibitor. Now, a new study investigating the relationships among age, response to anti–programmed cell death protein 1 (PD-1)...
Study Finds Increased Risk in Common Cancers in Female Night Shift Workers
In 2007, the International Agency for Research on Cancer classified shift work with circadian disruption or chronodisruption as a probable human carcinogen. Now, a meta-analysis investigating whether long-term shift work increases the risks of common cancers in women has found that, overall, night...
Novel Imaging Method for Predicting Immunotherapy Response
Although cancer immunotherapy can produce dramatic responses, only a minority of patients benefit from such therapy. Being able to differentiate treated responders from nonresponders early in the course of therapy would help to triage nonresponding patients away from ineffective therapies, reducing ...
Alcohol Intake Associated With Modest Increase in Risk of Melanoma
Although alcohol consumption is associated with increasing the risk of many cancers, including liver, pancreatic, colon, rectal, and breast, the link between alcohol and higher risk of melanoma is equivocal. Now, a large prospective study by Rivera et al investigating the link between alcohol...
Investigational Immunotherapy Appears Safe and Somewhat Active in Advanced Melanoma
The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Khalil et al in Clinical Cancer Research. IMD-20D7S is a...
Ratio of Certain Immune Cells in the Blood to Tumor Burden Correlated With Outcome for Melanoma Patients Treated With Pembrolizumab
Although some patients with melanoma experience durable responses to treatment with the anti–PD-1 (programmed cell death protein 1) therapy pembrolizumab (Keytruda), the majority of patients do not experience a durable clinical benefit from anti–PD-1 monotherapy, according to a study by ...
Combining AM0010 and Pembrolizumab Produced Antitumor Activity in Patients With Advanced Solid Tumors
A multibasket phase Ib study evaluating the clinical activity, tolerability, and antitumor activity of the cytokine-based immunotherapy AM0010 alone or in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) has found that in monotherapy, objective responses to AM0010 were ...
Combining Ipilimumab With Radiotherapy or Electrochemotherapy May Prolong Survival in Patients With Advanced Melanoma
The immunotherapy ipilimumab (Yervoy) has revolutionized the treatment of malignant melanoma and resulted in durable responses in 20% to 25% of patients with the cancer. A study by Theurich et al investigating the benefits of combining ipilimumab with local peripheral treatments, such as...
Citrus Fruit Consumption May Be Linked to An Increased Risk of Melanoma
A large population-based prospective analysis of the consumption of psoralen-rich citrus products and the risk of malignant melanoma has found that the melanoma risk was 36% higher in people who consumed citrus fruit or juice at least 1.6 times daily compared with those who consumed it less than...
One in Five Medicare Patients With Melanoma Experience Surgical Delays
A large retrospective cohort study of more than 32,000 Medicare beneficiaries diagnosed with melanoma has found that one in five patients experience a delay of surgery that is longer than 1.5 months. Those patients undergoing biopsy and surgery by dermatologists had the lowest risk for delay, which ...
NRAS Mutations in Advanced Melanoma Correlate With Increased Benefit From Immunotherapies
Researchers investigating whether tumor genotype correlates with benefit from immune therapy in melanoma has found that patients whose tumors had NRAS mutations had better response to immunotherapy and better outcomes than patients whose tumors had other genetic subtypes. The results suggest that...
Interactions Between Genetic Variants and Sun Behaviors May Influence Future Melanoma Risk
The combination of different patterns of sun exposure experienced by children and biomarkers of melanoma risk, such as the number of freckles or moles that develop as a result, may play a large role in future melanoma risk, a study investigating gene and environmental interactions has found....
Ipilimumab/Sargramostim Improves Overall Survival vs Ipilimumab Alone in Patients With Advanced Metastatic Melanoma
A randomized clinical trial of patients with advanced metastatic melanoma treated with ipilimumab (Yervoy), an immune checkpoint inhibitor, in combination with sargramostim (Leukine), an immune stimulant, vs ipilimumab alone, has found a 1-year survival rate of 68.9% vs 52.9% in the ipilimumab-only ...
New Screening Approach Identifies Cancer Mutations in Melanoma That May Lead to More Effective Immunotherapies
Although cancer immunotherapy with adoptive transfer of tumor-infiltrating lymphocytes represents an effective treatment for patients with metastatic melanoma, the antigen targets recognized by these effective tumor-infiltrating lymphocytes remain unclear. According to a new study, a novel...
Five or More Blistering Sunburns in Early Life May Raise Melanoma Risk by 80%
According to a large study of Caucasian women investigating chronic sun exposure over long durations in adulthood and sun exposure in early life, those who had at least five blistering sunburns when they were 15 to 20 years old had a 68% increased risk for basal cell carcinoma and squamous cell...
Phase I Trial of New Antibody-Drug Conjugate Shows Promise Against All Forms of Melanoma
A small clinical study of a new investigational antibody-drug conjugate called DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or ocular melanoma has found the drug to be safe and tolerable and demonstrated early evidence of antitumor activity. The findings were presented...
Nonmelanoma Skin Cancer Linked to Other Cancers, Especially in Young Survivors
A study by Ong et al has found that people who had nonmelanoma skin cancer were at an increased risk for subsequently developing melanoma and a spectrum of 29 other cancer types. The risk was especially high among people who develop nonmelanoma skin cancer before the age of 25. The findings are...
Study Identifies Key Mechanism Involved in Promoting Melanoma Proliferation
Researchers have identified a microRNA, miR-146a, that accelerates in the presence of BRAF and NRAS genetic mutations—which occur in 70% of melanoma cases—by activating the Notch signaling pathway. The finding could provide a new drug development target for patients with melanoma. The...
Novel BRAF Fusions Identified in 'Pan-Negative' Melanomas
A study by Sosman et al has identified two novel BRAF fusions in melanomas previously considered to be negative for molecular targets. In addition, these “pan-negative” melanomas were found to be sensitive to MEK inhibitors. According to the study, BRAF fusions define a new molecular...
Studies Reveal Multiple Gene Alterations Responsible for Drug Resistance in BRAF-Mutated Melanoma
Two studies using whole-exome sequencing of treatment-resistant BRAF-mutated melanomas have identified multiple gene alterations, mostly affecting the MAPK pathway. Molecularly profiling BRAF-mutated melanoma patients at the time of resistance may improve their care by tailoring combinations of...
New Studies Provide Insight Into Melanoma Drug Resistance Pathways and Strategy for Obtaining Durable Responses
Approximately 50% of metastatic melanomas harbor the BRAF mutation, and although most of these melanomas respond dramatically to treatment with BRAF inhibitors, such as vemurafenib (Zelboraf) and dabrafenib (Tafinlar), nearly all develop resistance to the drugs within 7 to 8 months. While previous...
NCI Scientists Use NanoString Technology to Identify Targets for Melanoma Immunotherapy
Researchers from the National Cancer Institute (NCI) have identified seven targets that could potentially be used to develop new immunotherapies for patients with metastatic melanoma. Their findings could increase the number of patients eligible for adoptive immunotherapy. The study was reported in ...
Single Injection of PV-10 Being Tested in the Treatment of Advanced Melanoma
A new study underway at Moffitt Cancer Center in Tampa, Florida, is investigating whether an intralesional injection of PV-10 (a substance derived from Rose Bengal, a staining agent that has been used to assess eye damage), is effective in reducing tumors and the spread of cancer in patients with...
